### Pfizer's Q3 2025 Earnings: A Resilient Performance Amidst Challenges Pfizer Inc. has reported a robust third-quarter profit of **$3.54 billion**, exceeding analyst expectations despite a **5.9% decline in revenue** primarily attributed to falling COVID-19 product sales. The company has successfully navigated these challenges by leveraging strong performances from its core drug portfolio, leading to an upward revision of its earnings per share (EPS) guidance for the full year 2025. This financial resilience is underscored by a landmark agreement with the U.S. government, which provides long-term business clarity, and early clearance for a significant acquisition aimed at enhancing its competitive edge in the obesity market [https://wtop.com/news/2025/11/pfizer-q3-earnings-snapshot][https://investingnews.com/pfizer-reports-solid-third-quarter-2025-results-raises-and-narrows-2025-eps-guidance]. ### Breakdown of Pfizer's Q3 Performance 1. **Financial Highlights** - **Profit**: $3.54 billion, surpassing expectations. - **Revenue**: $16.65 billion, meeting estimates despite a decline. - **EPS**: Beat estimates by **37%**, reported at **$0.87** [https://indexbox.io/blog/pfizer-q3-2025-profit-hits-354-billion-topping-expectations][https://www.indexbox.io/blog/pfizer-q3-2025-earnings-revenue-meets-estimates-eps-beats-by-37]. 2. **Core Drug Performance** - Growth in key products like **Eliquis** and **Vyndaqel** has offset the revenue drop from COVID-related sales. - Non-COVID drug sales have significantly contributed to profit margins and overall financial health [https://benzinga.com/markets/earnings/25/11/48620368/pfizers-core-drugs-offset-covid-revenue-drop-lifts-2025-profit-outlook-despite-tariffs][https://business-news-today.com/pfizer-q3-2025-earnings-beat-forecasts-as-non-covid-drug-sales-lift-margins-and-eps-guidance]. 3. **Strategic Developments** - Pfizer has reached a **landmark agreement** with the U.S. government, enhancing its long-term business outlook. - The company has secured early Federal Trade Commission (FTC) clearance for its proposed acquisition of Metsera, aimed at strengthening its position in the obesity treatment market [https://investingnews.com/pfizer-reports-solid-third-quarter-2025-results-raises-and-narrows-2025-eps-guidance][https://investorshangout.com/pfizers-q3-performance-shows-revenue-challenges-and-cost-control-446186-]. ### Summary of Findings 1. **Strong Financial Results**: Pfizer's Q3 2025 earnings reflect a **$3.54 billion profit**, driven by effective management of core drug sales despite a decline in COVID-19 product revenues. 2. **Positive EPS Guidance**: The company has raised its full-year EPS guidance, indicating confidence in its ongoing performance and strategic initiatives. 3. **Strategic Positioning**: The recent agreement with the U.S. government and the acquisition of Metsera are pivotal moves that enhance Pfizer's competitive landscape, particularly in the obesity market. In conclusion, **Pfizer's Q3 2025 results demonstrate resilience and strategic foresight**, positioning the company well for future growth despite current market challenges. The combination of strong core drug performance and strategic agreements suggests a positive trajectory for the remainder of the fiscal year [https://indexbox.io/blog/pfizer-q3-2025-earnings-revenue-meets-estimates-eps-beats-by-37][https://investorshangout.com/pfizers-q3-earnings-show-resilience-amid-covid-revenue-decline-445625-].